KRAS G12C Lung Cancer
Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2025
2026
2027
2028
AkesobioIBI351+AK112
Clinical Trials (1)
Total enrollment: 39 patients across 1 trials
A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation
Start: Apr 2025Est. completion: Mar 202839 patients
Phase 2Not Yet Recruiting
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
4h ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
4h ago
Office Administrator
SystImmune
4h ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
4h ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
4h ago
Working Student Active Sourcing Support (m/f/d)
Mindpeak
Hamburg
4h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space